Download pdf - GANNET53 A drug strategy targeting stabilised mutant p53 Figure … · 2015. 9. 7. · Bérard Lyon • AGO Research GmbH • NOGGO eV • ARCAGY GINECO • Universitätsmedizin Göttingen

A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer

PROJECT�PARTNERS�

Medical� University� Innsbruck� •� Katholieke� Universiteit� Leuven� •� Charité� Universitätsmedizin� Berlin� •� Medizinische�

Universität�Wien�•�Universitätsklinikum�Hamburg-Eppendorf�•�Assistance�Publique-Hôpitaux�de�Paris�•Centre�Léon�

Bérard� Lyon� •� AGO� Research� GmbH� •� NOGGO� eV� •� ARCAGY� GINECO� •� Universitätsmedizin� Göttingen� •� xailabs�

GmbH� •� ONCOLAB� Diagnostics� GmbH� •� Kliniken� Essen-Mitte� •� Technische� Universität� Dresden� •� Centre� François�

Baclesse�Caen�•�Ernst-Moritz-Arndt-Universität�Greifswald�•�Otto-von-Guericke-Universität�Magdeburg

This project has received funding from the

European Union’s Seventh Framework Programme for research, technological

development and demonstration under grant agreement no 602602.

GANNET53 A drug strategy targeting stabilised mutant p53

to fight metastatic platinum-resistant ovarian cancer EUROPEAN PROJECT

Sponsor: Medical University of Innsbruck, Austria, Department of Obstetrics and Gynecology

Coordinator: Prof. Dr. Nicole Concin

Figure 1: THE GANNET53 PROJECT PARTNERS

ORGANISATION GROUP LEADER

Medical University Innsbruck, AUSTRIA

Nicole Concin Christian Marth

Katholieke Universiteit Leuven, BELGIUM

Ignace Vergote

Charité - Universitätsmedizin Berlin, GERMANY

Jalid Sehouli Ioana Braicu

University Medical Centre Hamburg-Eppendorf, GERMANY

Sven Mahner

Medical University of Vienna, AUSTRIA

Alexander Reinthaller Dan Cacsire Castillo

Assistance Publique – Hôpitaux de Paris, FRANCE

Hôpital européen Georges-Pompidou Hôpital Tenon

Eric Pujade-Lauraine

Centre Anticancereux Léon Bérard, FRANCE

Isabelle Ray-Coquard

AGO Research GmbH, GERMANY

Sven Mahner











Nord-Ostdeutsche Gesellschaft für Gynaek-ologische Onkologie, GERMAN

Jalid Sehouli

ARCAY – GINECO Association de Recherche dans le Cancers dont Gynécologique – Groupe des Investigateurs Nationaux dans l’Etude des Cancers Ovariens, FRANCE

Eric Pujade-Lauraine

University Hospital Goettingen – Georg-August University Goettingen, GERMANY

Ute M. Moll

OncoLab Diagnostics GmbH, AUSTRIA

Robert Zeillinger

xailabs GmbH, GERMANY

Salvatore Vanasco

Kliniken Essen Mitte, Evang. Huyssens-Stiftung/Knappschaft GmbH, GERMANY

Philipp Harter

Technical University of Dresden University Hospital Carl Gustav Carus Dresden, GERMANY

Ulrich Canzler

Centre François Baclesse Centre de Lutte Contre le Cancer (CLCC) de Caen, FRANCE

Florence Joly-Lobbedez

University of Greifswald University Clinic Greifswald, GERMANY

Alexander Mustea

University of Magdeburg University Clinic Magdeburg, GERMANY

Atanas Ignatov











Figure 2: THE GANNET53 RECRUITMENT STRATEGY

Figure 3: THE GANNET53 PHASE II STUDY DESIGN











B

A

Figure 4: Proximity Ligation Assay (PLA) detecting Hsp90-mutp53 interaction applied on: FFPE ovarian cancer tissue (left), and ascites of an ovarian cancer patient (right)

Figure 5: Immunofluorecence staining of circulation tumour cells (CTC) from blood samples. A: Positive control of T47D cells spiked in leucocytes of a healthy donor; B: Example of a CTC detected in blood of an ovarian cancer patient.

LEGAL NOTE: All rights to the images displayed in Figures 4 and 5 are reserved by the GANNET53 consortium